📰 Image Misinterpretation News
Image Misinterpretation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Image Misinterpretation. Real-time updates on events, politics, business and more.
May 29, 2024
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations by its collaborators
October 5, 2023
Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery
October 3, 2023
− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered –For U.S audiences onlyMONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in...
July 29, 2023
FDA-approved in May 2023, POSLUMA is commercially available through 36 radiopharmacies across the United States
May 30, 2023
- POSLUMA will be commercially available in the United States in early June 2023 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative
April 19, 2022
ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now be
May 5, 2021
RadioMedix & Curium Announce DetectnetTM (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines® Share Article RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs). ST. LOUIS, Mo. (PRWEB) ...
December 14, 2020
Share this article Share this article INDIANAPOLIS, Dec. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that qualified physicians may now enroll patients in the study New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning at New IDEAS-Study.org. New IDEAS builds off the historic IDEAS Study, the largest Alzheimers disease study ever conducted with over 18,000 participants. 1 The new study will enroll 7,000 participants and investigate the impact of amyloid posi...